MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-19-2024
Renalytix AI plc Operating Income 2011-2026 | RNLX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Renalytix AI plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.6 M | -42.2 M | -53.2 M | -31.9 M | -10.3 M | -42.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.3 M | -53.2 M | -34.9 M |
Quarterly Operating Income Renalytix AI plc
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.09 M | - | -6.55 M | -8.64 M | -8.89 M | - | -10.9 M | -9.65 M | -11.7 M | - | -14.5 M | -13.8 M | - | - | -8.07 M | -8.61 M | - | - | - | - | - | - | - | - | - | -567 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -567 K | -14.5 M | -8.84 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
54 M | $ 8.96 | 1.01 % | $ 597 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 13.67 | 0.15 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.94 | 0.43 % | $ 721 M | USA |
 |
DexCom
DXCM
|
912 M | $ 68.13 | 2.7 % | $ 26.6 B | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 154.1 | 1.4 % | $ 7.64 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.47 | 0.87 % | $ 931 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 88.35 | 1.34 % | $ 11.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 103.93 | 0.08 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.57 | 4.11 % | $ 471 M | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 168.8 | 2.43 % | $ 29 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 17.35 | 0.35 % | $ 2.25 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 99.75 | 2.19 % | $ 8.23 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.86 | 0.7 % | $ 92.8 K | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 195.49 | 2.14 % | $ 139 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 122.2 | 2.45 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 199.41 | 0.23 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.35 B | $ 113.82 | 1.78 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.13 | 1.35 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 9.02 | 7.13 % | $ 256 M | Israel |
 |
NeoGenomics
NEO
|
-116 M | $ 8.31 | 0.85 % | $ 1.06 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.26 | 1.59 % | $ 2.01 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 79.31 | 1.03 % | $ 5.35 B | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.42 | 4.04 % | $ 426 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 454.33 | 0.15 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Celcuity
CELC
|
-113 M | $ 114.35 | -0.48 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.74 | 1.95 % | $ 397 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
-541 M | $ 200.3 | 1.33 % | $ 19.7 B | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.2 | 0.42 % | $ 833 M | USA |